AUSTIN, Texas--(BUSINESS WIRE)--Feb 28, 2013--ArthroCare Corp. (NASDAQ: ARTC), a leader in developing state-of-the-art, minimally invasive surgical products, has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its SpeedLock HIP Knotless Fixation implant. SpeedLock HIP is a PEEK (polyether-etherketone) implant that is indicated for soft tissue fixation to bone in the hip. Primarily used in acetabular labral reattachment and hip capsular repair, the implant is designed to provide a precise and stable construct with a streamlined technique. SpeedLock HIP complements ArthroCare’s line of Coblation wands and suturing technologies to provide a portfolio of enabling surgical tools for hip arthroscopy.
ArthroCare develops and manufactures surgical devices, instruments, and implants that strive to enhance surgical techniques as well as improve patient outcomes. Its devices improve many existing surgical procedures and enable new minimally invasive procedures. Many of ArthroCare’s devices use its internationally patented Coblation technology. This technology precisely dissolves target tissue and limits damage to surrounding healthy tissue. ArthroCare also develops surgical devices utilizing other patented technology including its line of soft tissue fixation products as well as re-usable surgical instruments. ArthroCare is leveraging these technologies in order to offer a comprehensive line of surgical devices to capitalize on a multi-billion dollar market opportunity across several surgical specialties, including its two core product areas consisting of Sports Medicine and Ear, Nose, and Throat as well as other areas such as spine, wound care, urology and gynecology.